Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.

Clinical pharmacology and therapeutics - 1 Oct 2003

Niemi Mikko, Leathart Julian B, Neuvonen Mikko, Backman Janne T, Daly Ann K, Neuvonen Pertti J

Abstract excerpt

OBJECTIVE: Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C8 on the pharmacokinetics and pharmacodynamics of the meglitinide analog antidiabetic drug repaglinide. METHODS: We genotyped 28 healthy volunteers who had participated in our pharmacokinetic studies on repaglinide for variant alleles of the CYP2C8 gene. Each subject ingested a 0.25-mg dose of repaglinide,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Cytochrome P-450 CYP2C8

Share to Half-Life

Share to Hypoglycemic Agents

Share to Linear Models

Share to Piperidines

Source

Identifiers

PMID: 14534525
DOI: 10.1016/S0009-9236(03)00228-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.PMID 14534525Read ↗

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.Semantic proximity Read ↗

CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.Semantic proximity Read ↗

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Semantic proximity Read ↗

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.Semantic proximity Read ↗

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.Semantic proximity Read ↗

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.Semantic proximity Read ↗

PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.Semantic proximity Read ↗

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.